# Pharming Group N.V. ADS each representing 10 (PHAR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.23, market value $795 million.

## Valuation
- **P/E (trailing): 80.2×** (5-yr avg 1795.6×, 3-yr avg 4417.5×). Pharming Group N.V. ADS each representing 10 trades at 80.2× trailing earnings, well below its own five-year average of 1795.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 36.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.30**. A PEG of 0.30 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 4.3%** (5-yr avg 0.2%). Free cash flow equals 4.3% of the market value, above its five-year average of 0.2%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.2%**. The inverse of the P/E: 1.2% of the price is earned each year.

## Profitability
- **Gross margin: 86.5%**. Pharming Group N.V. ADS each representing 10 keeps 86.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 3.4%**. 3.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.7%**. 0.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 0.9%**. 0.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 1.9%**. Each dollar of assets produces 1.9% of profit.

## Growth
- **Revenue growth (1 yr): 26.6%** (3-yr 22.3%/yr, 5-yr 12.1%/yr). Revenue grew 26.6% over the last year, against 12.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 122.2%** (3-yr -40.5%/yr, 5-yr -40.8%/yr). Earnings per share rose 122.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 36.8%/yr**. Free cash flow has compounded at 36.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Interest coverage: 0.8×**. Operating profit covers interest only 0.8×: fragile.
- **Current ratio: 2.59** (quick 2.59). Current assets cover the next year's liabilities 2.59 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Pharming Group N.V. ADS each representing 10 does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -24.5%** (YTD -36.4%, 3-mo -10.5%). The shares are down 24.5% over twelve months including dividends.
- **From 52-week high: -47.4%** (16.7% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.05** (volatility 66%). Beta of 1.05 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PHAR · Page: https://foliofundamentals.com/stocks/phar

Not investment advice.